Patient representatives' contributions to the benefit‐risk assessment tasks of the European Medicines Agency scientific committees

Lignende værker

• The risk-benefit task of research ethics committees: An evaluation of current approaches and the need to incorporate decision studies methods
  af: Bernabe, Rosemarie D L C, et al.
  Udgivet: (2012)
• The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia
  af: Rose, Klaus, et al.
  Udgivet: (2015)
• The European Medicines Agency Review of Ofatumumab (Arzerra®) for the Treatment of Chronic Lymphocytic Leukemia in Patients Refractory to Fludarabine and Alemtuzumab: Summary of the Scientific Assessment of the European Medicines Agency Committee for Medicinal Products for Human Use
  af: Gravanis, Iordanis, et al.
  Udgivet: (2010)
• The European Medicines Agency Review of Bosutinib for the Treatment of Adult Patients With Chronic Myelogenous Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
  af: Hanaizi, Zahra, et al.
  Udgivet: (2014)
• The fiduciary obligation of the physician-researcher in phase IV trials
  af: Bernabe, Rosemarie DLC, et al.
  Udgivet: (2014)